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Adoptive T cell transfer therapy, the ex vivo activation, expansion, and subsequent administration of tumor-reactive T cells, is
already the most eﬀective therapy against certain types of cancer. However, recent evidence in animal models and clinical trials
suggests that host conditioning interventions tailored for some of the most aggressive and frequent epithelial cancers will be needed
to maximize the benefit of this approach. Similarly, the subsets, stage of diﬀerentiation, and ex vivo expansion procedure of tumorreactive T cells to be adoptively transferred influence their in vivo eﬀectiveness and may need to be adapted for diﬀerent types
of cancer and host conditioning interventions. The eﬀects of adoptively transferred tumor-reactive T cells on the mechanisms of
endogenous (host-derived) antitumor immunity, and how to maximize their combined eﬀects, are further discussed.

1. Introduction
It has been more than 50 years now since Thomas and
Burnet first proposed the hypothesis that the immune system
could identify and eradicate transformed or malignant cells,
confirming earlier observations by Paul Ehrlich that an
“overwhelming frequency” of carcinomas could be repressed
by the immune system. This intrinsic ability of the immune
system to provide control against malignancies has since
been refined and termed immunosurveillance [1–4]. Despite
the presence of immunosurveillance properties within the
immune system, immunocompetent patients still develop
cancers, yet these tumors are often less immunogenic than
those that develop in immunosuppressed hosts. These and
other observations led to the demonstration that tumors
are imprinted by their immune environment, and this
imprinting facilitates their transformation into populations
that can more eﬀectively resist the pressure exerted by the
immune system to eradicate them [5–7]. This process, in
which the immune system acts both positively to inhibit
the progression of tumors and negatively to mold the
establishment of tumors that can evade its recognition, or
worse to promote the advancement of tumor development,

is referred to as immunoediting [3, 8]. Thus, the immune
system can prevent or promote tumor progression.

2. Myeloid Leukocytes Accumulate at Tumor
Locations and Induce Immunosuppression
Professional antigen presenting cells (APCs) with adequate stimulatory capacity are necessary within the tumor
microenvironment (TME) to induce suﬃcient eﬀector cells
or cytokines to maintain their tumor-fighting capacity.
However, tumor-bearing hosts do not appropriately present
tumor antigens. Instead, they mobilize immature myeloid
cells that include precursors of macrophages, dendritic cells
(DCs), and neutrophils. These cells, generically termed
Myeloid-Derived Suppressor Cells [9] (MDSCs), massively
accumulate at splenic and solid tumor locations, where
they contribute to tumor progression by providing growth
factors, as well as paracrine support for the formation of
blood vessels [10–15]. Most importantly, MDSCs abrogate
antitumor immune responses through multiple mechanisms
that include, at least, the production of L-Arginase, NO
and reactive oxygen species [10, 16–22], and the tyrosine
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nitration of the T cell receptor [23]. Because of the heterogeneous nature of the precursors recruited to tumor
locations as immature MDSCs, more diﬀerentiated but
still immunosuppressive macrophages or dendritic cells are
also frequently found in the tumor microenvironment.
In tumors, the precise categorization of myeloid cells is
therefore complicated by a high degree of phenotypic overlap
and also depends on specific microenvironments. In ovarian
cancer, for instance, we have repeatedly demonstrated that
the most abundant leukocyte subset in the SOLID tumor
microenvironment in humans, and in both tumor masses
and ascites in mice, expresses low but detectable levels of
phenotypic markers of bona fide DCs, including CD11c,
DEC205, CD86, and MHC-II (10, 13–15, 22, 24, 25).
Irrespective of their overlapping phenotypic characterization, we have repeatedly demonstrated that when these
tumor leukocytes receive specific activating signals, they can
functionally process full-length OVA in vitro [14, 24] and
in vivo [22, 25], as well as eﬀectively present processed
SIINFEKL to T cells [10, 15, 22, 25].
Yet, while DCs are also abundant in the microenvironment of many other tumors, functional mature DCs capable
of stimulating an antitumor response are not found in high
frequencies in human breast cancer, prostate cancer, ovarian
cancer, or renal cell carcinoma [26–30]. Cancer cells produce
various factors such as VEGF [31–36] and IL-6 [31, 37]
that suppress DC diﬀerentiation and maturation [38, 39]. At
the same time, cytokines that promote DC diﬀerentiation,
such as granulocyte–macrophage colony-stimulating factor
(GM-CSF) and IL-4 and Th1 polarizing cytokines like IFNγ and IL-12, are seldom found in large quantities in many
human cancers, and ovarian cancer in particular [40, 41].
Thus, this skewed cytokine profile promoted by the tumor
impairs the eﬀective priming of an immunostimulatory DC
phenotype and promotes the transition of DC precursor cells
recruited to the tumor microenvironment into a suppressive
population. Importantly, in several cancer systems, DCs in
both the tumor microenvironment and peripheral blood can
revert to an immunostimulatory phenotype in vitro and can
prime tumor-specific T cell responses [40, 42]. Nonetheless,
the modulation of APCs does not appear to be strong enough
to overcome the tolerogenic environment of many tumors.
In fact, in ovarian cancer, patients receiving multiple rounds
of fully matured myeloid DCs were not able to regain T
cell function after their in vivo association with suppressive
tumor-associated plasmacytoid DCs [40].

3. T Cells Exert Spontaneous Immune Pressure
against Cancer Progression
In contrast, despite the heterogeneous nature of the CD3+
T cell compartment, the presence of T cells in the various
malignancies generally correlates with improved clinical
outcomes to the point that CD3+ T cells are considered
the only immune population capable of exerting antitumor
eﬀects against established tumors [43, 44].
The evidence of immune cell infiltrates and their ability
to mount antitumor responses in various tumor systems have
led investigators to target tumors through modulation of
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the immune response. Immune-based therapies are delivered
either through active immunotherapy, in which vaccines
such as peptides, tumor antigens, nucleic acids, engineered
tumor cells, or tumor-pulsed DCs are used to activate host
antitumor immune cells to react against the tumor, or passive
immunity wherein antibodies or antitumor lymphocytes
are transferred into tumor-bearing hosts to directly induce
tumor cell destruction [45]. Passive immunotherapy has
revealed high success rates in certain implications, however,
as most protocols direct responses against a single antigen/epitope, and tumors often modulate their expression of
particular antigens, there is often a high degree of ineﬃcacy.
Active immunotherapy in both mouse and human tumor
systems have resulted in potent antitumor responses and
regression, and is beneficial in the fact that rather than
restricting responses to a single epitope /antigen, polyclonal
responses can readily be induced.
While both forms of immunotherapy have demonstrated
positive results, they each have drawbacks. The ideal system
would entail passive therapeutics that can immediately start
eliminating the tumor while inducing an active endogenous
response to continue the tumor eradication. Under ideal
circumstances, transferred T cells could migrate to the tumor
site and directly lyse tumor cells while releasing endogenous
immune cells from the tumor-induced immunosuppression.
However, the tumor environment is usually so immunosuppressive that it is diﬃcult to appropriately release these brake
mechanisms on antitumor responses.

4. Adoptive Cell Transfer Therapy Induces
the Rejection of Advanced Tumors
Adoptive cell transfer therapy (ACT), the ex vivo activation,
expansion, and subsequent administration of tumor-reactive
T cells, is a vastly successful therapy against certain cancers.
In fact, ACT is currently the most eﬀective therapy against
metastatic melanoma, with objective regressions reported
in 50% of patients [46–49]. Adoptive T cell therapies
have focused on the use of CD8+ T cells, as they have
relatively long clonal expansion times, can specifically target
tumors, and are easily subjected to genetic manipulations.
Lymphodepletion has been used to enhance the persistence
of transferred T cells in vivo. By eliminating suppressive
populations, removing cytokine sinks-endogenous cells that
compete with the transferred cells for cytokines that promote
their activation and function, and through augmenting
the function and availability of APCs, lymphodepletion is
thought to enhance the antitumor response. In fact, in
melanoma, ACT was only eﬀective after prior lymphodepletion of patients, and this combination produced distinct
and reproducible responses in roughly 50% of melanoma
patients being treated with ACT.
ACT has also displayed remarkable success in human
clinical trials against Epstein-Barr virus- (EBV-) related disorders, immunoblastic lymphoma, and also Non-Hodgkin’s
disease [45, 50–55]. Yet, although these findings are optimistic for the future of adoptive immunotherapy, these
systems are markedly diﬀerent in that they are virally induced
tumor systems, and the T cells are directed against foreign,
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rather than self, antigens. In most malignancies, being
nonviral, T cell antigenic targets are often self-antigens. This
further complicates the ability to produce large numbers of
tumor-reactive T cells since, not only do they usually occur
in only low frequencies [56], but also most T cells that
robustly respond to self antigens have either been eliminated
during thymic development or rendered nonfunctional by
local tolerizing mechanisms [57–59]. In fact, T cell adoptive
therapies have not resulted in impressive clinical benefits yet
against the most lethal-epithelial-tumors [60–62]. Therefore,
the expansion protocols for transferred T cells need to
maximize both the quality and quantity of tumor-reactive T
cells produced. As such, much work has gone into identifying
strategies to optimize the ex vivo expansion of tumorreactive T cells for ACT.

5. Ex Vivo Generation of Tumor-Reactive
T Cells for Adoptive Transfer
The main sources of modulation of the conditions for T cell
expansion include the antigen source, the cytokine environment, and the source and eﬀector stage of the T cells before
expansion [57]. Various adoptive cell transfer regimens entail
the nonspecific, polyclonal expansion of T cells through
mitogenic stimulation as with phytohaemagglutinin, or
antibodies to CD3/CD28. These nonspecific manipulations
have achieved significant response rates against hepatocellular carcinoma, myeloma, non-Hodgkin’s lymphoma, and
Hodgkin’s disease [45, 63–66]. This would indicate that
not only do the direct tumorlytic eﬀects of CD8+ T cells
contribute to the beneficial responses of ACT, but also that
secreted factors may also play a role.
The expansion of T cells against tumors of nonviral
origin pose diﬀerent challenges, including the low frequency
of CTLs against self antigens [45]. In humans, the low
frequency of precursor populations of tumor-reactive T cells
has been circumvented by prior vaccination of patients
with helper peptide-based vaccines. Vaccination of breast
and ovarian cancer patients with HER-2/neu peptide-based
vaccines supplemented with GM-CCSF adjuvant treatment
over a six-month period increased the precursor frequency
of HER-2/neu-specific T cells that were capable of secreting
IFN-γ in response to tumour and directly lyse HER-2/neu
expressing tumors [67]. Similarly, vaccination of breast cancer patients with MUC-1 helper peptide vaccines produced
CTLs reactive against MUC-1 expressing tumors [68]. Recent
mouse models of melanoma have shown that these timeconsuming and often cumbersome vaccination strategies
may be bypassed by appropriate in vitro programming of the
transferred T cells. These protocols have an additional benefit
over helper peptide vaccination in that they can facilitate the
expansion of polyclonal lymphocyte cultures.
An innovative approach used to circumvent the low frequency of tumor-reactive T cells in cancer patients has been
the genetic manipulation of autologous T cells to express
either T cell receptors (TCR) targeted to tumor-associated
antigens (TAA), or with chimeric receptors encompassing
a B cell receptor to a particular antigen complexed with
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the TCR signaling domain (so-called T-bodies) [48, 69].
In a phase I clinical trial, administration of allogeneic T
cells that recognize the HLA-A2-restricted peptide MART1 induced a partial response in one patient, while remaining
patients did not yield any overall response [70]. In another
study, autologous peripheral blood lymphocytes retrovirally
transduced with the MART-1 TCR induced complete regression in two patients with metastatic melanoma, but had
no eﬀect on the remaining 13 patients in the cohort [48].
While this technique provides a method for bypassing the
customary low numbers of tumor-specific T cells capable of
being harvested from cancer patients, it poses the problem of
limiting the potential antitumor response to a single epitope
which, if downregulated by the tumor, would render the
procedure useless.
Alternatively, T cells may be modified with genes to
inhibit the induction of apoptosis or senescence. The antiapoptotic genes BCL-2 and BCL-xL have been introduced
into T cells resulting in the extended survival of such cells
even under conditions that would usually promote apoptosis
[71, 72]. Recently, it was demonstrated that both mouse and
human tumor-reactive T cells could be eﬀectively transduced
with siRNA to downmodulate their expression of PD-1.
As anticipated, this prevented inhibitory signaling through
the PD-1/PD-L1 inhibitory pair and instead generated T
cells with enhanced proliferation and immune function as
determined through IL-2 and IFN-γ secretion [73]. This
technique provides access to a new realm of ACT, wherein T
cells can be engineered to specifically avoid the debilitating
TME without the need to induce systemic methods for
disrupting immunosuppression.
Other manipulations include the introduction of
autocrine growth signals into T cells before transfer to
enhance their in vivo proliferation. This was first attempted
through the overexpression of IL-2 on T cells, which had
no eﬀect on the tumorlytic capacity of these transferred T
cells. In contrast, unlike IL-2, IL-15 does not promote the
expansion of Tregs and when overexpressed in human T
cells prolonged the expression of antiapoptotic genes thus
the persistence of tumor specific cells and enhanced their
antitumor responses [74, 75].

6. Relative Efficacy of Individual T Cell
Differentiation Subsets
The therapeutic eﬀects of ACT have been commonly
attributed to the in vivo expansion and antitumor activity
of transferred lymphocytes. Correspondingly, major eﬀorts
have been focused on promoting long-term persistence
of adoptively transferred T cells [76]. Various in vitro
manipulations have been evaluated to enhance the in vivo
persistence of transferred T cells. Thus, the T cells have
been cultured in the presence of, or coadministered with, the
cytokines IL-2, IL-7, IL-12, IL-15, and IL-21 [77, 78]. While
each has been found to have its own specific benefits and
demonstrated to enhance the therapeutic eﬀects of adoptive
immunotherapy in mouse models of melanoma, their eﬀects
have been related to the promotion of a specific eﬀector
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phase of the transferred T cell. This has led to several studies
evaluating the eﬃcacy of particular T cell diﬀerentiation
subsets in adoptive T cell therapy against cancer.
Although eﬀector memory T cells (TEM ) are superior to
central memory T cells (TCM ) at inducing in vitro cytotoxicity of transformed cell cultures, they have poor replicative
capacity in vivo, and TCM exert superior therapeutic benefits
to TEM cells [76, 79–82]. Central memory T cells, being the
least diﬀerentiated of the antigen experienced population
of T cells, and being thought to have the capacity for selfrenewal, and for retaining the option to diﬀerentiate into
a vast repertoire of T cell populations, was for some time
considered the ideal starting population of cells for expansion protocols [83]. These TCM cells can undergo robust
expansion in response to secondary exposure to antigen and
secrete copious levels of IL-2, in stark contrast to TEM cells.
It was later found that compared with more diﬀerentiated
eﬀector lymphocytes, or memory T cells, early eﬀectors have
a higher capacity for in vivo expansion, which is associated
with enhanced therapeutic eﬀects against melanoma [84].
Thus, fewer early eﬀector T cells specific to the gp100 antigen
were necessary to induce regression of melanoma in mice.
More recently still, we demonstrated for the first time that
naı̈ve or briefly activated T cells can induce potent antitumor
responses in adoptive T cell transfer experiments, which was
subsequently confirmed in an independent study [24, 85,
86]. These eﬀects coincided with the in vivo diﬀerentiation
of these precursor cells into cytotoxic cells and the induction
of endogenous immune responses, which were found to be
necessary for the therapeutic eﬀects.

7. Tumorlytic Activity of CD4+ versus
CD8+ T Cells
Most investigations on the antitumor eﬀects of T cells have
centered around CD8+ T cells due to their high expression in
various malignancies, ease of isolation and in vitro manipulation, and their keen ability to directly lyse tumor cells
[87]. Several reports had demonstrated the eﬃcacy of CD8+
T cells in inducing potent antitumor responses, although it
is widely accepted that their ability to clear tumors requires
further manipulation of the T cell directly, for example,
through genetic elimination of inhibitory surface receptors
[88], addition of specific TCRs or of the hosts through
irradiation [89], or other immune interventions. Still, the
contribution of CD4+ T cells to adoptive immunotherapy,
particularly against epithelial cancers, remains controversial.
However, it is widely accepted that a great deal of the
failures that arise from the use of CD8+ T cells stem from
the absence of CD4+ T cell help necessary for maintaining
their in vivo functionality [90–93]. Despite the immense
amount of data supporting the positive contribution of
certain subsets of CD4+ T cells in enhancing the eﬃcacy
of function and persistence of CD8+ T cells, manipulations
utilizing CD4+ T cells have been very limited. CD4+ T
cells present as a particularly diﬃcult population of cells to
work with as they do not proliferate as eﬀectively in vitro
as do CD8+ T cells [94], and very little progress has been
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made in the identification of class II restricted peptides [87].
Furthermore, most tumors do not express MHC-II and are
therefore not directly recognized by CD4+ T cells.
Due to the great degree of homogeneity within the
CD4+ T cell compartment and thus the wide spectrum of
opposing eﬀects potentially inducible by these cells, as well
as the deficit in knowledge of MHC-II (CD4) restricted
epitopes [87], the role of CD4+ T cells in antitumor
immunity remains an investigative area that has been largely
neglected. Furthermore, the majority of studies into this
population have focused on the adverse eﬀects of regulatory
CD4+ T cells, thus creating a negative reputation for these
cells in tumor immunology. Still, there have been several
reports demonstrating the beneficial role of CD4+ T cells
in antitumor immunity, providing rationale for undertaking
further investigations in this area.
Evidence from various studies show that in the absence of
CD8+ T cells, CD4+ T cells were still capable of eliminating
both haematologic and solid tumors [95–97]. Using transgenic T cells specific to diﬀerent H-Y antigens, Perez-Diez
and colleagues were able to demonstrate in 6 diﬀerent tumor
models that CD4+ T cells were more eﬀective than CD8+ T
cells (or a mixed population of both CD4+ and CD8+ T cells)
at rejecting tumors even in the absence of MHC-II expression
on the tumor cells [98]. There exists the possibility that the
diﬀerences in antigen epitopes and TCR avidities may be
responsible for these observed eﬀects. Importantly, however,
the authors found that antigen presentation by host cells was
required at the eﬀector phase for this tumor rejection by
primed CD4+ T cells and speculate that this may be through
the activation of local macrophages and other cells but never
validated this.
Recently, two articles confirmed the positive contribution of CD4+ T cells in adoptive immunotherapy against
melanoma, both describing a direct tumorlytic eﬀect of these
transferred T cells [85, 99]. In both cases, small numbers of
naı̈ve CD4+ T cells specific to the Trp1 melanoma antigen
were transferred into irradiated recipient mice bearing established B16 melanoma. Interestingly, these cells expanded
robustly and importantly diﬀerentiated into cytotoxic CD4+
T cells that directly eliminated B16 melanomas [85, 99].
These tumors do not express MHC-II, but it was further
shown that the secretion of IFN-γ by the transferred CD4 led
to the upregulation of MHC-II on these tumors making them
direct targets of the transferred T cells. In one context, further immune intervention by antibody-mediated blockade of
the coinhibitory receptor CTL-associated antigen 4 (CTLA4) on T cells augmented the antitumor activity through
enhancing the expansion of the transferred T cells, increasing
IFN-γ levels, thus cytotoxicity, and reducing the number of
Tregs present.

8. Alternative Mechanisms of Enhanced
Antitumor Immunity Mediated by
CD4+ T Cells
While the studies referred to above underscore the direct
tumorlytic potential of CD4+ T cells, it is generally accepted
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that most human tumors do not express MHC-II and
are therefore insensitive to CD4+ T cell-mediated cytolysis. However, other than directly lysing tumors, CD4+ T
cells have been demonstrated to contribute to antitumor
responses through the provision of cytokine support, the
maintenance and survival of CD8+ T cells and through the
expression of CD40L [100–104]. Indeed, we demonstrated
that adoptively transferred CD4+ T cells, through CD40LCD40 interactions, license tumor-associated DCs to prime
endogenous antitumor CD8+ T cells [24, 86]. Thus, DCs
that in the tumor microenvironment contributed to the
promotion of immunosuppressive conditions, when given
the appropriate stimuli, including CD40 signaling through
CD40L- expression on transferred T cells, were capable
of priming antitumor responses. This concurs with their
ability to uptake tumor antigens while retaining an immature
phenotype such that the mere provision of this additional
stimulus was capable of reversing their phenotype. This
induction of endogenous responses had greater ramifications, as we demonstrated that these host immune responses
remained active for prolonged periods and protected naı̈ve
mice from challenge with the same tumor [24, 86].
In addition to directly promoting CD8+ T cell functionality, CD4+ T cells have been shown to secrete various
cytokines that activate host antigen presenting cells, and
their coadministration with CD8+ T cells revealed enhanced
therapeutic benefits coupled with the induction of a robust
central memory response [105–107]. Thus, Hunder et al.
provided evidence with a single case of eﬀective adoptive
T cell therapy utilizing NY-ESO-1-specific CD4+ T cells
cultured with IL-7 and IL-2 for the treatment of a patient
with metastatic melanoma who had not received prior
lymphodepletion or vaccination therapy [49].
Moreover, the infiltration of immune populations in
ovarian cancer is modulated by chemokines, which therefore
influence the clinical outcome. Elucidation of factors that
contribute to the infiltration of immune cells into the ovarian
cancer microenvironment (but not breast cancer) [108–110],
revealed that tumors with significant T cell infiltrates had
elevated levels of various chemokines, including CCL5, the
production of which was found to be restricted to the lymphocyte population rather than the tumor cells [111, 112].
Our studies demonstrate that CD4+ T cells expanded against
tumor antigen secrete high levels of CCL5, thus promoting
the recruitment of CCR5 expressing T cells and DCs to
the tumor site [24, 86]. The chemokine receptor CCR5 is
expressed on memory/eﬀector like T cells and is associated
with Th1 type responses. Our findings have been mirrored
by a report from Dobrzanski et al. that demonstrates that
the adoptive transfer of MUC1 specific CD4+ T cells increase
endogenous T cell activity and the survival of patients with
residual recurrent epithelial ovarian cancer, and that these
eﬀects corresponded with increased expression of CCR5 and
associated ligands on tumor responsive T cells [113].
Collectively, these data indicate that CD4+ T cells contribute positively to the induction of antitumor responses
achieved through adoptive T cell transfer regimens in ovarian
cancer, and likely in other tumors. We found that CD4+
T cells could independently delay tumor progression but a
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mixed population of CD4+ and CD8+ T cells induced greater
antitumor eﬃcacy against our aggressive model of ovarian
cancer. Thus, we now appreciate the fact that it is the quality
rather than quantity of adoptively transferred T cells that is
more relevant for achieving positive clinical outcomes, and
that the appropriate host conditioning strategies must be
employed to retain their functionality and maximize their
therapeutic eﬃcacy.
It should be noted, however, that preliminary results
from ongoing trials in patients with metastatic melanoma
suggest that the inclusion of antitumor CD4+ T cells in the
adoptively transferred T cell population results in poorer
clinical responses, which are associated with the expansion
of the regulatory T cell compartment [114]. It is therefore
likely that the antitumor eﬀectiveness of CD4+ T cells could
depend on the type of cancer or the host conditioning
strategy applied to support the adoptively transferred lymphocytes. For instance, high doses of IL-2 are administered to
patients receiving antitumor T cells, but not always to tumorbearing mice in these published reports. The preferential
eﬀect of IL-2 on regulatory T cells contained among the
CD4+ T cells could at least partially explain the discrepancies
between mouse systems and these clinical results, and help to
design improved approaches.

9. Immunosuppressive Tumor
Microenvironmental Networks Abrogate
the Activity of Adoptively Transferred
Tumor-Reactive T Cells against
Aggressive Epithelial Tumors
Adoptive T cell therapy, while highly successful for many
nonepithelial cancers, has not yet been eﬀective in the most
frequent and aggressive epithelial cancers, likely due to the
peculiarities of their respective microenvironments. In ovarian cancer, for instance, adoptively transferred autologous
T cells directed at the α-folate receptor disappeared rapidly
(often within a month) in association with increasing levels
of an undetermined inhibitory factor [115]. It appears that
many of the immunotherapies attempted against advanced
epithelial cancers have the capacity to induce the production
of potent CTLs, yet this has not proven suﬃcient to translate
to improved survival in all cases, likely as a result of tolerogenic factors within the tumor microenvironment. Recent
reports of induction of antitumor immune responses upon
combination of CTLA-4 blockade along with vaccination in
ovarian cancer patients [116, 117] highlight the relevance
of overcoming immunosuppression, particularly in conjunction with other immune strategies to produce antitumor
immunity. Therefore, it has become abundantly clear from
the wealth of experimental data in this field that due to
the diversity of mechanisms employed by tumors to evade
immune destruction, the appropriate immunotherapeutic
regime may not simply target an individual aspect, but may
need to incorporate strategies that address multiple immune
pathways.
Several reports propose various methods for enhancing
the in vivo survival of adoptively transferred lymphocytes.
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One such method is through the sublethal irradiation of
tumor-bearing hosts to create space to accommodate the
expansion of the transferred T cells. We found that even
under the context of irradiation and depleting regulatory
myeloid cells from tumor locations, our transferred T cells
did not persist for long periods, although the combination of
irradiation and immunosuppressive myeloid cell depletion
enhanced the therapeutic benefit observed when T cells
were transferred into tumor-bearing mice. As an individual
intervention, elimination of immunosuppressive myeloid
cells in tumor-bearing mice disrupted tumor vasculature,
produced an immunogenic boost, and thereby delayed
tumor progression [15]. Accordingly, the elimination of
this immunosuppressive population of cells bolstered the
in vivo expansion and therapeutic eﬀectiveness of adoptive
immunotherapy in our ovarian cancer models, but not the
persistence of transferred lymphocytes [24, 86].
While irradiation did not enhance the survival of the
transferred T cells, it likely enhanced the immunogenicity
through inducing the death of some tumor cells, and thus
releasing tumor antigen that could trigger host immune
responses. Furthermore, irradiation can cause upregulation
of certain molecules on tumor cells, such as MHC-I or the
death receptor Fas, that render them more immunogenic and
flag them as better targets for immune elimination [118].
The persistence of transferred T cells correlates with
greater eﬃcacy in most cancer systems, thus enhancing the
survival of these transferred T cells is a future direction to be
taken into consideration. Stimulation of CD40 and Toll-like
Receptor 3 on ovarian cancer infiltrating DCs converts them
from immunosuppressive to immunostimulatory cells and
boosts T cell-mediated antitumor immune responses [22].
Such pretreatment of tumor bearing hosts before ACT may
extend the survival of transferred T cells. Ongoing studies in
our laboratory should define the potential of this approach.
Notwithstanding, the impact of standard treatment
modalities should not be disregarded and immune therapies
should probably be administered in conjunction with,
rather than, in place of such. Surgical debulking may
still be a necessary procedure for the removal of large
tumor masses, while, as we and others have demonstrated,
chemotherapy/radiation therapy may bolster the eﬀects of
immunotherapies. Finally, immune-based therapies may add
to the antitumor armament by eradicating residual disease
and activating endogenous antitumor responses that persist
ideally in the memory compartment to prevent metastatic
lesions and to control recurrences.
Such trimodal approaches (surgery plus chemotherapy/radiation plus immunotherapy) probably represent the
future in the battle against epithelial cancers. Immunotherapeutic interventions, since largely hypothetical, are tested in
patients with late stage, very advanced disease, or recurrent
disease that is often refractory to standard therapies, in
which case the eﬃcacy of any intervention is highly unlikely
and mostly improbable. Trials in patients whose disease has
not progressed as far may prove to reveal more favorable
clinical outcomes, and, through the elicitation of protective
endogenous immune responses, may prevent recurrence and
increase the rate of survival of endothelial cancer patients.
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Drastic measures need to be taken to defeat the grim eﬀects
of the most devastating cancers.

10. Effect of ACT on Endogenous Ongoing
Antitumor Immunity
The prevailing concept surrounding ACT is that successful
ACT requires the persistence of the transferred T cells,
which are considered the ultimate mediators of the antitumor response. Importantly, the contribution of endogenous
responses to the eﬃcacy of immune-based therapies has
been a largely neglected area. As stated above, however,
our studies in ovarian cancer models show that such
endogenous responses are not only important, but crucial
to the elimination of established tumors and the induction
of persistent memory responses [24]. As described above, we
found that our T cells briefly primed against tumor antigens
do not persist for very long (as in human ovarian cancer)
but instead elicit the awakening of host immune populations
that induce sustained antitumor responses [24, 86]. Existing
(although obviously suboptimal) antitumor responses were
significantly boosted in mice receiving adoptively transferred
tumor-reactive T cells. Most importantly, endogenous T cellmediated responses were long-lived and more persistent than
the activity of transferred lymphocytes. Thus, adoptively
transferred T cells stimulate the awakening of host immune
responses and host cells after ACT developed the ability to
recognize and react to tumor antigens. The transferred T
cells required perforin for maximal eﬀectiveness suggesting
that these transferred CTLs induce immunogenic tumor
death triggering the release of tumor antigen that may prime
DC activation. CD4+ T cells provided further costimulatory
molecules to complete the activation of these DCs indicating
that the adoptively transferred CD4+ and CD8+ T cells
cooperate to induce their antitumor eﬀects.
These results imply that while persistence and direct
antitumor activity of adoptively transferred T cells is crucial
for their therapeutic potential, and how they impact existing
immune responses may be another variable to optimize
in a clinical context. Unleashing endogenous antitumor
immunity may also result from host-conditioning strategies
and synergize with ACT. Thus, interventions aimed to transform tumor microenvironmental cells from an immunosuppressive to an immunostimulatory phenotype (such as
CD40+TLR agonists) may be ideal to boost the expansion,
persistence, and therapeutic activity of both adoptively
transferred and endogenous tumor-reactive lymphocytes.

11. Concluding Remarks
Despite a great deal of eﬀort being dedicated to the development of new therapies, there has been minimal improvement
in the survival rate for most cancers including epithelial ovarian cancer. Strategies that have proven successful in certain
malignancies have not produced similar results in epithelial
cancers like ovarian cancer, highlighting the complexities
existing within the microenvironment of individual cancers
and emphasizing the need to consider each tumor as an
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independent entity. T cell therapies often fail due to the
tolerogenic environment in which the T cells are placed and
that integrating techniques that reduce the immunosuppressive nature of the tumor microenvironment will enhance the
eﬃcacy of ACT and make it a viable treatment modality.
Newly developed immunotherapies will need to address multiple immune pathways and circumvent various mechanisms
of immune evasion and importantly need to incorporate
strategies that contribute to the induction of endogenous
responses which we had found to be not only beneficial,
but crucial to the elimination of established tumors and the
induction of persistent memory responses. It is apparent that
the appropriate T cell polarization and diﬀerentiation will
need to be identified in individual tumor systems for the
optimal function of anticancer lymphocytes, and to break the
tumor-induced paralysis of host immune responses. Furthermore, while most studies have focused on the contribution of
or administration of cytotoxic CD8+ T cells, it is becoming
increasingly clear that the coadministration of appropriate
CD4+ T cell subsets may be advantageous to the therapeutic
eﬀects of ACT, particularly through the elicitation of endogenous antitumor responses, and their incorporation into ACT
regimens should be further investigated.
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